Responce: Histostem 4

I was pleased that the article from CNN on the Histostem company supported an opinion I've had for a while. I think that using stem cells from the umbilical cord should be more widely practiced. Reading about how it has helped people that were suffering with leukemia restored my faith in the study of stem cells from the umbilical cord. Until now I have not been able to find current information about hematopic stem cells, I didn't even know the correct term for them.

This article has been enlightening to say the least. Histostem's projected annual profit has once again proved that stem cell research is a current and developing topic. If a company's worth can jump from 1.8 billion to 3.5 billion in the course of only 3 years, it has to be something important. The Stem Cell Therapy International company from which Histostem developed, would be something I would like to look into. In the future months I would like to research the progress that they have made to ensure that the topic isn't going to fade quickly.

Notes: Histostem 4

Histostem Ltd. in South Korea is a subsidary company from Stem Cell Therapy International, inc.

hematopic stem cells are being used to treat patients with lukemia.

this is being practiced in Hong Kong, China

Histostem is the first Korean company to provide this type of hematopic stem cells, they're stem cells from the umbilical cord.

Histostem is expecting a 25% annual growth rate for their company, making them a large developing power. $1.8 billion in 2009 to an estimated $3.5 billion by 2012.

Histostem has treated 500 patients to date through this type of hematopic treatment.

Their designs and discoveries have, so far, earned them 6 patents and they currently have 5 more pending.

They are one of the few companies out there that's able to profit from their new technology.